Literature DB >> 15221875

Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data.

Mark B Bromberg1, Orly Carter.   

Abstract

Corticosteroids have been used to treat neuromuscular disorders for many years. With few randomized, controlled trials, efficacy has been established primarily from empirical data. This has led to a range of treatment regimens varying in terms of initial dosing, dosing schedules, and taper rates. The goals of this review were to examine the literature for data concerning corticosteroid pharmacokinetics and for evidence-based treatment regimens in several prototypic neuromuscular disorders. The results provide a number of sound principles for corticosteroid use, but also indicate that corticosteroid regimens and patient management are largely based on empirical clinical experiences.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221875     DOI: 10.1002/mus.20075

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

Review 1.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard Ac Hughes; Man Mohan Mehndiratta; Yusuf A Rajabally
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

Review 2.  Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

Authors:  Anne Louise Oaklander; Michael Pt Lunn; Richard Ac Hughes; Ivo N van Schaik; Chris Frost; Colin H Chalk
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

Review 3.  Corticosteroids for Guillain-Barré syndrome.

Authors:  Richard Ac Hughes; Ruth Brassington; Angela A Gunn; Pieter A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2016-10-24

4.  Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.

Authors:  Eugenia Piscitelli; Marida Massa; Bernardo Maria De Martino; Carmela Simona Serio; Gaspare Guglielmi; Giovanni Colacicco; Francesco Tuccillo; Francesco Habetswallner
Journal:  Eur J Hosp Pharm       Date:  2020-10-29

Review 5.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

6.  Autoimmune neuromuscular disorders in childhood.

Authors:  Hugh J McMillan; Basil T Darras; Peter B Kang
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

7.  Balanced Free Essential Amino Acids and Resistance Exercise Training Synergistically Improve Dexamethasone-Induced Impairments in Muscle Strength, Endurance, and Insulin Sensitivity in Mice.

Authors:  Jiwoong Jang; Jin-Ho Koh; Yeongmin Kim; Hee-Joo Kim; Sanghee Park; Yewon Chang; Jiyeon Jung; Robert R Wolfe; Il-Young Kim
Journal:  Int J Mol Sci       Date:  2022-08-27       Impact factor: 6.208

Review 8.  Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.

Authors:  Paolo Ripellino; Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Autoimmune Dis       Date:  2014-01-14

Review 9.  Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy.

Authors:  Mattia Quattrocelli; Aaron S Zelikovich; Isabella M Salamone; Julie A Fischer; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2021
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.